您的位置: 首页 > 农业专利 > 详情页

COMBINED USE OF A TRKA INHIBITOR AND AN EPHA2 INHIBITOR FOR USING IN THE TREATMENT OF SOLID CANCERS, AND METHOD FOR THE PROGNOSIS OF SURVIVAL OF A PATIENT WHO HAS A SOLID CANCER
专利权人:
发明人:
Robert Toillon,Xuefen Le Bourhis,Cyril Corbet,Leo Aubert,Matthieu Guilbert
申请号:
US15511739
公开号:
US20170258871A1
申请日:
2015.09.07
申请国别(地区):
US
年份:
2017
代理人:
摘要:
The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the prognosis of survival of a patient who has a solid cancer, comprising a step of detecting the expression of TrkA and EphA2 in a biological sample of the patient, the co-expression of TrkA and EphA2 being associated with a poor prognosis of survival of the patient.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充